Immunogenicity of hepatitis B vaccine in patients with inflammatory bowel disease and the benefits of revaccination

Journal of Gastroenterology and Hepatology (Australia)

Volumn 30, Issue 1, 2015, Pages 92-98

  Cossio Gil, Yolima ^a   Martínez Gómez, Xavier ^a   Campins Martí, Magda ^a   Rodrigo Pendás, José Ángel ^a   Borruel Sainz, Natalia ^b   Rodríguez Frías, Francisco ^a   Casellas Jordà, Francesc ^b  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Hepatitis B vaccine; Immunogenicity; Inflammatory bowel disease

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; HEPATITIS A HEPATITIS B VACCINE; HEPATITIS B SURFACE ANTIBODY; INFLIXIMAB; METHOTREXATE; MYCOPHENOLIC ACID; RECOMBINANT HEPATITIS B VACCINE; TACROLIMUS; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE;

ADULT; ARTICLE; COHORT ANALYSIS; COMORBIDITY; CROHN DISEASE; ENZYME IMMUNOASSAY; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; IMMUNOGENICITY; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVACCINATION; ULCERATIVE COLITIS; AGE; IMMUNIZATION; IMMUNOLOGY; MIDDLE AGED;

ADULT; AGE FACTORS; COHORT STUDIES; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION, SECONDARY; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84919608801     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12712     Document Type: Article

References (43)

1. Rahier JF, Moutschen M, Van GA etal. Vaccinations in patients with immune-mediated inflammatory diseases. Rheumatology (Oxford) 2010; 49: 1815-1827.
2. World Health Organization. Immunization, vaccines and biologicals-hepatitis B. Who. 2012 July 1. Cited 10 Aug 2012. Available from URL: http://www.who.int/mediacentre/factsheets/fs204/en/index.html
3. Ali T, Yun L, Shapiro D, Madhoun MF, Bronze M. Viral infections in patients with inflammatory bowel disease on immunosuppressants. Am. J. Med. Sci. 2012; 343: 227-232.
4. Hou JK, Velayos F, Terrault N, Mahadevan U. Viral hepatitis and inflammatory bowel disease. Inflamm. Bowel Dis. 2010; 16: 925-932.
5. Millonig G, Kern M, Ludwiczek O, Nachbaur K, Vogel W. Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening? World J. Gastroenterol. 2006; 12: 974-976.
6. Colbert C, Chavarria A, Berkelhammer C. Fulminant hepatic failure in chronic hepatitis B on withdrawal of corticosteroids, azathioprine and infliximab for Crohn's disease. Inflamm. Bowel Dis. 2007; 13: 1453-1454.
7. Centers for Disease Control and Prevention. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. Surveill Summ. 2011; 60: 1-64.
8. Mast EE, Margolis HS, Fiore AE etal. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR. Recomm. Rep. 2005; 54(RR-16): 1-31.
9. Alper CA, Kruskall MS, Marcus-Bagley D etal. Genetic prediction of nonresponse to hepatitis B vaccine. N. Engl. J. Med. 1989; 321: 708-712.
10. Fisman DN, Agrawal D, Leder K. The effect of age on immunologic response to recombinant hepatitis B vaccine: a meta-analysis. Clin. Infect. Dis. 2002; 35: 1368-1375.
11. Shaw FE, Guess HA, Roets JM etal. Effect of anatomic injection site, age and smoking on the immune response to hepatitis B vaccination. Vaccine 1989; 7: 425-430.
12. Winter AP, Follett EA, McIntyre J, Stewart J, Symington IS. Influence of smoking on immunological responses to hepatitis B vaccine. Vaccine 1994; 12: 771-772.
13. Kotton CN. Vaccines and inflammatory bowel disease. Dig. Dis. 2010; 28: 525-535.
14. Melmed GY. Vaccination strategies for patients with inflammatory bowel disease on immunomodulators and biologics. Inflamm. Bowel Dis. 2009; 15: 1410-1416.
15. Rahier JF, Ben-Horin S, Chowers Y etal. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J. Crohns Colitis 2009; 3: 47-91.
16. Sands BE, Cuffari C, Katz J etal. Guidelines for immunizations in patients with inflammatory bowel disease. Inflamm. Bowel Dis. 2004; 10: 677-692.
17. Wasan SK, Baker SE, Skolnik PR, Farraye FA. A practical guide to vaccinating the inflammatory bowel disease patient. Am. J. Gastroenterol. 2010; 105: 1231-1238.
18. Ooi CJ, Fock KM, Makharia GK etal. The Asia-Pacific consensus on ulcerative colitis. J. Gastroenterol. Hepatol. 2010; 25: 453-468.
19. Altunoz ME, Senates E, Yesil A, Calhan T, Ovunc AO. Patients with inflammatory bowel disease have a lower response rate to HBV vaccination compared to controls. Dig. Dis. Sci. 2012; 57: 1039-1044.
20. Vida PL, Gomez CF, Garcia SV etal. Adequate rate of response to hepatitis B virus vaccination in patients with inflammatory bowel disease. Med. Clin. (Barc) 2009; 132: 331-335.
21. Gisbert JP, Villagrasa JR, Rodriguez-Nogueiras A, Chaparro M. Efficacy of hepatitis B vaccination and revaccination and factors impacting on response in patients with inflammatory bowel disease. Am. J. Gastroenterol. 2012; 107: 1460-1466.
22. Sempere L, Almenta I, Barrenengoa J etal. Factors predicting response to hepatitis B vaccination in patients with inflammatory bowel disease. Vaccine 2013; 31: 3065-3071.
23. Das K, Gupta RK, Kumar V, Kar P. Immunogenicity and reactogenicity of a recombinant hepatitis B vaccine in subjects over age of forty years and response of a booster dose among nonresponders. World J. Gastroenterol. 2003; 9: 1132-1134.
24. Han K, Shao X, Zheng H etal. Revaccination of non- and low- responders after a standard three dose hepatitis B vaccine schedule. Hum. Vaccin. Immunother. 2012; 8: 1845-1849. [Epub ahead of print].
25. Pettit NN, DePestel DD, Malani PN, Riddell J. Factors associated with seroconversion after standard dose hepatitis B vaccination and high-dose revaccination among HIV-infected patients. HIV Clin. Trials 2010; 11: 332-339.
26. Johnson & Johnson. VITROS Immunodiagnostic Products aHBs Calibrator and Reagent Pack IFU No. GEM1205-V 4.0. Ortho Clinical Diagnostic. 2013. Cited 20 Feb 2013. Available from URL: http://apps.orthoclinical.com/TechDocs/TechDocSearch.aspx?culture=es-es
27. Moscandrew ME, Loftus EV. Diagnostic advances in inflammatory bowel disease (imaging and laboratory). Curr. Gastroenterol. Rep. 2009; 11: 488-495.
28. Sepulveda SE, Beltran CJ, Peralta A etal. Inflammatory bowel diseases: an immunological approach. Rev. Med. Chil. 2008; 136: 367-375.
29. Fattal-German M. Immunocompetence in the elderly. Ann. Pharm. Fr. 1992; 50: 13-24.
30. Kumar R, Burns EA. Age-related decline in immunity: implications for vaccine responsiveness. Expert Rev. Vaccines 2008; 7: 467-479.
31. Hutt HJ, Bennerscheidt P, Thiel B, Arand M. Immunosenescence and vaccinations in the elderly. Med. Klin. (Munich) 2010; 105: 802-807.
32. Agarwal N, Ollington K, Kaneshiro M, Frenck R, Melmed GY. Are immunosuppressive medications associated with decreased responses to routine immunizations? A systematic review. Vaccine 2012; 30: 1413-1424.
33. Van AS, Elkayam O, Agmon-Levin N etal. Vaccination in adult patients with auto-immune inflammatory rheumatic diseases: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for vaccination in adult patients with auto-immune inflammatory rheumatic diseases. Autoimmun. Rev. 2011; 10: 341-352.
34. Fiorino G, Peyrin-Biroulet L, Naccarato P etal. Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study. Inflamm. Bowel Dis. 2012; 18: 1042-1047.
35. Piazza M, Abrescia N, Picciotto L etal. Demonstration of the interchangeability of 2 types of recombinant anti-hepatitis-B vaccine. Boll. Soc. Ital. Biol. Sper. 1993; 69: 273-280.
36. Tung J, Carlisle E, Smieja M, Kim PT, Lee CH. A randomized clinical trial of immunization with combined hepatitis A and B versus hepatitis B alone for hepatitis B seroprotection in hemodialysis patients. Am. J. Kidney Dis. 2010; 56: 713-719.
37. Zhuang GH, Yan H, Wang XL, Wu Q, Wang LR, Gao HY. A five-year observation on efficacy of revaccination in children of non-response to hepatitis B vaccine. Zhonghua Yu Fang Yi Xue Za Zhi 2006; 40: 8-12.
38. Van der WM, Van DP, Chlibek R, Smetana J, Von Sonnenburg F. Hepatitis A/B vaccination of adults over 40 years old: comparison of three vaccine regimens and effect of influencing factors. Vaccine 2006; 24: 5509-5515.
39. Fonseca MO, Pang LW, de Paula CN, Barone AA, Heloisa LM. Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. Vaccine 2005; 23: 2902-2908.
40. Gisbert JP, Menchen L, Garcia-Sanchez V, Marin I, Villagrasa JR, Chaparro M. Comparison of the effectiveness of two protocols for vaccination (standard and double dosage) against hepatitis B virus in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 2012; 35: 1379-1385.
41. Tielemans CL, Vlasak J, Kosa D etal. Immunogenicity and safety of an investigational AS02(v)-adjuvanted hepatitis B vaccine in patients with renal insufficiency who failed to respond or to maintain antibody levels after prior vaccination: results of two open, randomized, comparative trials. Vaccine 2011; 29: 1159-1166.
42. Mowat C, Cole A, Windsor A etal. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011; 60: 571-607.
43. Wiedmann M, Liebert UG, Oesen U etal. Decreased immunogenicity of recombinant hepatitis B vaccine in chronic hepatitis C. Hepatology 2000; 31: 230-234.